Not division…But growth. Cells must grow PI3K GFR Akt Rheb Ras mTOR Tuberin/ Hamartin PTEN Neurofibromin Tuberous sclerosis complex Neurofibromatosis.

Slides:



Advertisements
Similar presentations
 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Basis of Gliomas slide presentation is not an independent educational.
Advertisements

TOR ( target of rapamycin) signaling Apr 4, 2005.
Insulin Signaling – Insulin Resistance Elmus G. Beale, Professor Texas Tech University Health Sciences Center Paul L. Foster School of Medicine PhD, Baylor.
TSC2 and Tuberous Sclerosis Complex Disease Laura Koontz Biology 169.
PI3K/Akt/mTOR.
Modeling of Acute Resistance to the HER2 Inhibitor, Lapatinib, in Breast Cancer Cells Marc Fink & Yan Liu Student Project Proposal Computational Cell Biology.
Survival signalling in myeloma
Targeting the IGF Pathway in Pediatric Sarcomas-Lessons Learned and Questions Raised Lee J. Helman, M.D. Scientific Director for Clinical Research,Center.
Signal Transduction Pathway Smorgasbord Ron Bose, MD PhD Biochemistry and Molecular Cell Biology Programs Washington University School of Medicine Molecular.
Genetic Variations in the PI3K/PTEN/AKT/mTOR Pathway are Associated with Clinical Outcomes in Esophageal Cancer Patients Treated with Chemoradiotherapy.
Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.
TSC and LAM: Current Treatment Options and Clinical Trials
The nucleolus (nucleoli) non-membrane bound structure composed of proteins and nucleic acids, transcribe ribosomal RNA (rRNA) and assemble it within the.
Hypertrophic signalling Identify contraction-induced growth signals Describe the composition and regulation of mTORC1 Describe the effectors of mTOR Explain.
GENOMIC ANALYSIS OF OVER 400 SARCOMAS – Gregory M. Cote – J. Butrynski, J. Shen, J. Morgan, Z. Duan, D. D’Adamo, G. Nielsen, S. George, F. Hornicek, G.
Molecular Biology of Cancer. CANCER TAKES TIME CANCER IS A DISEASE OF GENETIC MUTATIONS ACCUMULATION OF MANY MUTATIONS CAUSES CANCER.
CDCA7 A case study in cellular regulation
Ρύθμιση κυτταρικού κύκλου & Εισαγωγή στην κυτταρική σηματοδότηση Γιώργος Ρασιδάκης Επ. Καθηγητής Παθολογικής Ανατομικής, Ιατρική Σχολή ΕΚΠΑ Adj. Assistant.
Figure S1 A. B. * * * * * * * * * * * * *. Figure S2 A. B. Fold Increase OxPhos Genes.
Specialized signaling pathways 1: RTK associated pathways
Cell Cycle Regulator and Tumor Development
Protein synthesis Translation.
TSC1 and Facial Angiofibromas
Bio 714 Foster TGF-beta/cell cycle material. Points: Suppression of either PLD or mTOR in the absence of serum results in apoptosis Importantly, suppression.
Restriction Point G0 TGF-  and Cell Cycle Progression Cyclin D CDK4/6 Cyclin E CDK2 TGF-  Cell Growth Checkpoint G1-pm SG1-psG2M.
TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.
Insulin and Amino Acid Signaling Through mTOR in Perfused Rat Liver Jessica Biegler.
Date of download: 6/22/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. The protein products of tumor-suppressor genes often function.
TSC1 Tuberous Sclerosis 1
Translation. The enzyme: Amminoacyl-tRNA synthetase.
AMPK – Akt – mTOR AXIS IS A METABOLIC CHECKPOINT OF THE CELL
Combination with IGF1R, PI3K inhibitors
MYC, Metabolism and Cancer
by Rogelio Zamilpa, and Merry L. Lindsey
Tuberous Sclerosis TSC2/ Tuberin Alison Chappell.
TSC2 GENE ENCODES FOR TUBERIN
Figure 1 mTOR pathway activation
Dan Gordon  Gastroenterology  Volume 114, Issue 4, (April 1998)
The Akt-mTOR tango and its relevance to cancer
Kinase inhibitors: Vice becomes virtue
Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3- Kinase/AKT/Mammalian Target of Rapamycin Pathway  Gozde Akgumus, Fengqi.
Nat. Rev. Urol. doi: /nrurol
Alexander L. Fogel, BS, Sharleen Hill, MD, Joyce M.C. Teng, MD, PhD 
Figure 1 mTOR complex biology
In-vitro regulation of primordial follicle activation: challenges for fertility preservation strategies  Michael J. Bertoldo, Kirsty A. Walters, William.
The pathway signalling starts with the binding of insulin or growth factors to insulin receptors. The pathway signalling starts with the binding of insulin.
Maria M. Mihaylova, David M. Sabatini, Ömer H. Yilmaz  Cell Stem Cell 
Rapamycin: One Drug, Many Effects
Nat. Rev. Urol. doi: /nrurol
FGFR Signaling as a Target for Lung Cancer Therapy
An Emerging Role of mTOR in Lipid Biosynthesis
mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells
Martin J. Baker, Mariana Cooke, Marcelo G. Kazanietz  Cancer Cell 
AKT/PKB Signaling: Navigating the Network
Figure 1 The mTOR signalling pathway
Supplementary Figure 1 A B C CD56 D E F CD56.
Principles of Tumor Suppression
Volume 10, Issue 1, Pages (July 2002)
Rapamycin: One Drug, Many Effects
Multifunctional Tumor Suppressor
Long Zhang, Fangfang Zhou, Peter ten Dijke 
MYC on the Path to Cancer
mTOR and Akt Signaling in Cancer: SGK Cycles In
Long Noncoding RNAs and Hepatocellular Carcinoma
Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD 
Volume 13, Issue 15, Pages (August 2003)
Tobias B. Huber, Gerd Walz, E Wolfgang Kuehn  Kidney International 
BC Basics 2017.
Dysregulation of the mTOR Pathway Secondary to Mutations or a Hostile Microenvironment Contributes to Cancer and Poor Wound Healing  Richard A.F. Clark,
Presentation transcript:

Not division…But growth

Cells must grow

PI3K GFR Akt Rheb Ras mTOR Tuberin/ Hamartin PTEN Neurofibromin Tuberous sclerosis complex Neurofibromatosis type 1 (NF1) Cowden Syndrome Lhermitte-Duclos disease S6KeIF4E NPM ARF p68

Thinking about translation

The forgotten translation…top m RNA s Terminal Oligo Pyrimidine tracts: 5’-CTTTCTTCTC…

Raptor mLST8 mTOR Rictor mLST8 mTOR FKBP12 Actin cytoskeleton Ribosomal biogenesis Protein translation Rapamycin

PDK1 PTEN Mutations 5% LOH ~30% Akt Akt2 amplified < 5% S6K1 Amplified ~10% (17 q 23) PIK3CA Mutations in ~25% overall Gene amplification < 10% (~25%) (~45%) (<7%) ER + HER2 + ER + /HER2 + ER - /HER2 - ? m TOR NPM ? 4E-BP1 ? e If4e ? The growth pathway is subject to enormous mutation rates

PIK3CA mutations in ~25% of breast cancers (~25%) (~45%) (<7%) ER + HER2 + ER + /HER2 + ER - /HER2 - ~275 samples from ER + patients undergoing Letrozole therapy Developed sequencing pipeline for Exons 1,6,7,9,20 with GSC Goal 1: Attack the genotype Figure adapted from Cancer Res 65: 2554 Hypothesis: pik3ca mutations render tumors resistant to ER- and HER2-targeted therapies

CONSERVATION OF NUCLEOLAR STRUCTURE/FUNCTION RESIDENTSDRIFTERS NPM/B23 NCL/C23 Fibrillarin Cdc14B Nop5/Sik Bop1 R-proteins hnRNP’s TCOF1 NUMA1 Ki67 p19ARF Cdc14A TERT WRN ING1 PP1 SMN1 UBF Mdm2 MdmX Cyclin E p53 DKC1 PES1 BLM Mammals(~450) drosophilaYeast(~39)zebrafishxenopus

D. Trere (2000) Micron 31: UNIFORM AgNOR & SAPA SCORING METHOD

RIBOSOMAL GENES AND THE NUCLEOLUS FIVE rGENE CLUSTERS CHR. 13, 14, 15, 21, 22 OVER 400 TANDEM REPEATS ~47 KB REPEAT ELEMENT YIELDS 13KB TRANSCRIPT

Processing is everything

r rna modifications

Suppressing transcription…first important clue

Lots of steps to mess with…

Myc sends us another clue…

S6K eIF4E Protein Synthesis NPM Ribosomal Export rRNA Transcription CYTOPLASM NUCLEOLUS TIF1A RNA Pol I mTOR

Nuclear export nucleus cytosoplasm AAAAAAAA-3’ 5’ 60S 40S m TOR S6K NPM nucleolus Nucleophosmin acts in a late r RNA stage

Nucleophosmin is mutated in human cancers

nucleus cytosoplasm nucleolus 60S 40S 60S 40S AAAAAAAA-3’ 5’ PI3K S6K NPM r RNA Export Polysomes Protein synthesis This mutant is hyperactive in r RNA export

…The pathway can be addictive mTORC2 Rac1 NPM rRNA Export Rapamycin Neurofibromin K-Ras Polysomes Proteins None LY Rap Nf1+/+Nf1-/- Tubulin S6 P Neurofibromin controls the growth pathway

PI3K CELL SURVIVALCELL GROWTHCELL PROLIFERATION Nucleolar Integrity ARF/ p 53 Rapamycin ARF m TOR S6K NPM r RNA Export Polysomes Protein synthesis The pathway must have checks in place

THE INK4A-ARF LOCUS Fibrosarcomas Lymphomas Gliomas Melanomas Fibrosarcomas Lymphomas Gliomas 11 11 23 Ink4a / ARF Cyclin D-Cdk4Mdm2 Rb p 53 ?

Pol III 5S Pol I 5.8S18S 28S NUCLEOLUSNUCLEOPLASM 5S--- rp L5---NPM ARF 60S NUCLEAR EXPORT Synchronized ribosome export

Layers of potential targets… RTK Ras p85 p110 PDK1 AKT PTEN P P P P MDM2 IKK eNOS TSC1/2 GSK3  FOXO Myc mTOR Cyclin D p53 NF-  B p27kip1 Rheb cdk4 eIF4E NPM 28S 18S 5.8S 5S ARF S6K 4E-BP1 28S18S5.8S